Double-Punch combo trial aims to rev up immune system against tough cancers
NCT ID NCT04235777
Summary
This early-stage study is testing whether two new immunotherapy drugs, M7824 and PDS01ADC, can help the body's immune system fight advanced bladder, kidney, and related cancers that have spread. Researchers want to see if adding a precise, high-dose radiation treatment (SBRT) makes the drugs work better. The main goal is to find safe dose levels and see how well the treatments are tolerated by up to 100 adults with these cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.